Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology

Peptide Comparison

AHK-Cu vs Palmitoyl Dipeptide-6

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

AHK-Cu and Palmitoyl Dipeptide-6 share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer AHK-Cu has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; AHK-Cu's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

AHK-Cu

Cosmetic Clinical Studies

Palmitoyl Dipeptide-6

Cosmetic Clinical Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

AHK-Cu Palmitoyl Dipeptide-6
Class Copper tripeptide (cosmetic) Cosmetic lipopeptide (retinol-mimic)
Drug class Dermatologic Dermatologic
Mechanism Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp Activates retinoid-responsive genes without retinoid irritation
Route Topical Topical
Half-life Topical (no systemic) Topical
Dosage (research) Topical 0.01-0.1% Topical 1-3%
Evidence tier Cosmetic Clinical Studies Cosmetic Clinical Studies
Research depth 5 indexed (PubMed 1 · CT 0 · EPMC 4) —
Availability Cosmetic Cosmetic
Reported risks Skin irritation; theoretical copper issues Minimal

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick AHK-Cu or Palmitoyl Dipeptide-6?

AHK-Cu and Palmitoyl Dipeptide-6 share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer AHK-Cu has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; AHK-Cu's evidence base is currently denser.

What is the difference between AHK-Cu and Palmitoyl Dipeptide-6?

AHK-Cu is classed as Copper tripeptide (cosmetic); Palmitoyl Dipeptide-6 is classed as Cosmetic lipopeptide (retinol-mimic). Reported mechanism: AHK-Cu, Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp; Palmitoyl Dipeptide-6, Activates retinoid-responsive genes without retinoid irritation. Reported half-life: AHK-Cu, Topical (no systemic); Palmitoyl Dipeptide-6, Topical. Routes in published studies: AHK-Cu, Topical; Palmitoyl Dipeptide-6, Topical.

Which has stronger evidence, AHK-Cu or Palmitoyl Dipeptide-6?

AHK-Cu and Palmitoyl Dipeptide-6 sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. AHK-Cu is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 5 indexed studies. Palmitoyl Dipeptide-6 is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page.

Which is more accessible, AHK-Cu or Palmitoyl Dipeptide-6?

Neither AHK-Cu nor Palmitoyl Dipeptide-6 is an FDA-approved drug. Catalog status: AHK-Cu, Cosmetic; Palmitoyl Dipeptide-6, Cosmetic.

Are AHK-Cu and Palmitoyl Dipeptide-6 ever combined?

AHK-Cu and Palmitoyl Dipeptide-6 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…